PeptexLab laboratory logo

· Dosage Protocol

Retatrutide Pen Dosage Protocol

Written by PeptexLab Editorial Team · Research use only

Retatrutide supplied as a pre-filled multi-dose pen delivering a GIP/GLP-1/glucagon triple-agonist peptide. Educational protocols use titrated weekly subcutaneous injections. For research and educational use only.

Retatrutide Pen

Product

Retatrutide Pen

Multi-Target Peptide · Pre-Filled Pen

View product

Quick Start

The short version

If you only read one thing, read this. The four cards below are the whole protocol in plain English — the sections that follow just add the detail.

What is it

Retatrutide Pen

Retatrutide supplied as a pre-filled multi-dose pen delivering a GIP/GLP-1/glucagon triple-agonist peptide.

Typical dose

2–12 mg subcutaneous, once weekly

Start low, work up. See the phase table for a week-by-week ramp.

How often

Once weekly

Same time each day is easiest to remember and keeps levels steady.

Storage

2–8 °C, dark

Keep the mixed vial in the fridge. Powder can sit at room temp until you mix it.

Dosage Chart

Pen strength
30 mg / 3 mL (10 mg/mL)
Typical weekly range
2–12 mg subcutaneous, once weekly
Unit measurement
Pen dial in mg
Storage (in-use)
2–8 °C, protect from light
Route
Subcutaneous
Frequency
Once weekly

Handling

Dosing & Reconstitution Guide

The pen is pre-filled — no reconstitution required. Attach a fresh pen needle, prime the pen, dial the target dose, and inject subcutaneously.

Subcutaneous Protocol

PhaseDoseUnits / dial
Weeks 1–4 (Initiation)2 mg once weeklyDial 2 mg
Weeks 5–8 (Titration)4 mg once weeklyDial 4 mg
Weeks 9–12 (Standard)8 mg once weeklyDial 8 mg
Advanced (Higher end)12 mg once weeklyDial 12 mg

Frequency: once weekly subcutaneously. Slow uptitration reduces GI adverse effects.

Supplies Needed

Retatrutide 30 mg pen

Pre-filled multi-dose pen.

Pen needles

Fresh disposable pen needle each administration.

Alcohol swabs

For pen tip and injection site prep.

Refrigeration

Keep pen refrigerated when not in use.

Plain-English Glossary

Jargon, translated

A quick decoder for the terms you'll see across this page.

Subcutaneous (subQ)
Injected into the fatty layer just under the skin — not into muscle or vein. Easier and less painful than an IM shot.
Reconstitution
Mixing a dry powder with liquid (bacteriostatic water) to turn it into an injectable solution.
Lyophilized
Freeze-dried. The peptide arrives as a dry powder so it stays stable during shipping.
Bacteriostatic water
Sterile water with a tiny amount of preservative that prevents bacteria growth — used to mix peptides.
Units (on an insulin syringe)
The small tick marks on a U-100 syringe. 100 units = 1 mL. Most doses are just a few units.
Half-life
How long it takes your body to clear half of a dose. Guides how often you inject.
Titration
Starting low and slowly increasing the dose so your body can adjust.

Protocol Overview

  • Goal: Support metabolic research on multi-receptor incretin signaling.
  • Schedule: Once weekly subcutaneous injection.
  • Dose range: 2–12 mg, titrated slowly.
  • Storage: Refrigerated, protected from light.

Dosing Protocol

  • Start: 2 mg once weekly for four weeks.
  • Titrate in ~2 mg increments every 4 weeks if tolerated.
  • Timing: Consistent day of the week.
  • Cycle length: 12–24 weeks, then reassess.

Storage Instructions

  • Lyophilized product: room temperature, sealed and protected from light. Refrigeration acceptable.
  • Reconstituted product: 2–8 °C (35.6–46.4 °F) refrigerated, protected from light.
  • Do not freeze reconstituted solution.
  • Allow to reach room temperature before administration to reduce injection-site response.

Important Notes

  • Use a new sterile syringe for each administration.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Discard the vial if the solution becomes cloudy, discolored, or shows particulates.
  • Document daily dose and site rotation for consistency.
  • GI effects are dose-dependent — slow titration is the primary mitigation.

Mechanism

How This Works

Retatrutide is a triple agonist at the GIP, GLP-1, and glucagon receptors, combining incretin-driven satiety with glucagon-driven energy expenditure. The long fatty-acid side chain enables once-weekly pharmacokinetics.

Potential Benefits & Side Effects

  • Substantial reductions in body weight in phase-2 trials.
  • Improved glycemic parameters in type-2 diabetes research.
  • Reduced hepatic steatosis markers reported.
  • Common adverse effects: nausea, diarrhea, constipation.

Lifestyle Factors

  • Prioritize protein and resistance training to preserve lean mass.
  • Stay well hydrated.
  • Avoid high-fat meals near injection day.
  • Maintain consistent injection day for adherence.

Injection Technique

  1. 1. Attach a fresh pen needle and prime the pen.
  2. 2. Clean the injection site with alcohol.
  3. 3. Dial the target dose.
  4. 4. Pinch a skinfold; insert at 45–90° subcutaneously.
  5. 5. Depress fully, hold 5–10 seconds, withdraw.
  6. 6. Dispose of the pen needle in a sharps container.

Important note. This content is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment.

References

  1. 1

    Jastreboff et al., NEJM (2023)

    Retatrutide phase-2 trial in obesity

    View source
  2. 2

    Coskun et al. (2022)

    Triple-agonist pharmacology

    View source

Explore more

Browse all PeptexLab protocols

Every PeptexLab reference material has a dedicated dosage protocol page with reconstitution guides, phase schedules, and research references.

View all protocols